

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed the grant of a total of 180,000 options over ordinary shares in the Company (Options) under the Company's Share Option Plan 2019.

The Options have been allocated under the Share Option Plan 2019 and are exercisable between 1 December 2026 and 1 December 2031, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan is €2.26 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 1 December 2025. The terms of the Share Option Plan 2019 are available on the Company's website at https://faron.com/wp-content/uploads/2025/04/20250321_Share-Option-Plan-2019_Rules_EN_clean.pdf

The granted 180,000 Options entitle the option holders to subscribe for a total of 180,000 new ordinary shares in the Company, if exercised in full, and represent 0.16% of the fully diluted ordinary share capital of the Company.

Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities (PDMRs) and Company personnel:

Other PDMR

Jurriaan Dekkers	180,000
------------------	---------

Total other PDMRs	180,000
--------------------------	----------------

For more information, please contact:

IR Partners, Finland (Media)

Kare Laukkanen

+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi

FINN Partners, US (Media)

Alyssa Paldo

+1 847 791-8085
alyssa.paldo@finnpartners.com

Cairn Financial Advisers LLP (Nominated Adviser and Broker)

Sandy Jamieson, Jo Turner

+44 (0) 207 213 0880

Sisu Partners Oy (Certified Adviser on Nasdaq First North)

Juha Karttunen

+358 (0)40 555 4727

Jukka Järvelä

+358 (0)50 553 8990

About Bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. *Bexmarilimab* binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, *bexmarilimab* alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The company's lead asset, *bexmarilimab*, is a novel macrophage-guiding immunotherapy being investigated in multiple oncology settings. Further information is available at www.faron.com.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Jurriaan Dekkers

2	Reason for notification	Â Â Â										
a.	Position/Status	Person discharging managerial responsibilities										
b.	Initial notification/ Amendment	Initial notification										
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor											
a.	Name	Faron Pharmaceuticals Oy										
b.	LEI	7437009H31TO1DC0EB42										
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted											
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares ISIN: FI4000153309										
b.	Nature of the transaction	Grant of options made under the Faron Share Option Plan 2019										
c.	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td><td colspan="2"></td></tr><tr><td>â,-2.26</td><td>180,000</td><td colspan="2"></td></tr></table>			Price(s)	Volume(s)			â,-2.26	180,000		
Price(s)	Volume(s)											
â,-2.26	180,000											
d.	Aggregated information Â - Aggregated Volume Â - Price	Â Â Nil Â Â										
e.	Date of the transaction	2 December 2025										
f.	Place of the transaction	Turku Â										